NASDAQ:RNLX Renalytix (RNLX) Stock Price, News & Analysis $0.35 +0.05 (+16.58%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$0.30▼$0.3750-Day Range$0.23▼$0.5252-Week Range$0.22▼$3.20Volume1.04 million shsAverage Volume1.68 million shsMarket Capitalization$27.13 millionP/E RatioN/ADividend YieldN/APrice Target$3.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Renalytix alerts: Email Address Renalytix MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside753.5% Upside$3.00 Price TargetShort InterestHealthy3.95% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.30Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.30) to ($0.13) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.33 out of 5 starsComputer And Technology Sector413th out of 612 stocksMedical Laboratories Industry14th out of 18 stocks 3.5 Analyst's Opinion Consensus RatingRenalytix has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageRenalytix has only been the subject of 1 research reports in the past 90 days.Read more about Renalytix's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.95% of the outstanding shares of Renalytix have been sold short.Short Interest Ratio / Days to CoverRenalytix has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Renalytix has recently increased by 941.31%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldRenalytix does not currently pay a dividend.Dividend GrowthRenalytix does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for RNLX. Previous Next 2.9 News and Social Media Coverage News SentimentRenalytix has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.53 average news sentiment score of Computer and Technology companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Renalytix this week, compared to 1 article on an average week.Search Interest3 people have searched for RNLX on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat Follows6 people have added Renalytix to their MarketBeat watchlist in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Renalytix insiders have not sold or bought any company stock.Percentage Held by Insiders18.30% of the stock of Renalytix is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 9.92% of the stock of Renalytix is held by institutions.Read more about Renalytix's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Renalytix are expected to grow in the coming year, from ($0.30) to ($0.13) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Renalytix is -0.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Renalytix is -0.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRenalytix has a P/B Ratio of 2.34. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Renalytix's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Colonial MetalsCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar.In answer to this issue, we have released a Special Report to the public. About Renalytix Stock (NASDAQ:RNLX)Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix Plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; and Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was incorporated in 2018 and is based in New York, New York.Read More RNLX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RNLX Stock News HeadlinesJuly 11, 2024 | globenewswire.comRenalytix and Steno Diabetes Center Announce Precision Medicine Collaboration Marking First Expansion for KidneyIntelX Platform Beyond USJune 27, 2024 | globenewswire.comRenalytix Submits Hearing Request to Nasdaq Hearings Panel in Regard to Staff Delisting DeterminationJuly 27, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.June 14, 2024 | globenewswire.comMedicare Issues Final Coverage Determination for kidneyintelX.dkdMay 15, 2024 | investorplace.comRNLX Stock Earnings: Renalytix Misses EPS, Misses Revenue for Q3 2024May 15, 2024 | msn.comRenalytix AI GAAP EPS of -$0.08 beats by $0.01, revenue of $0.54M misses by $0.56MMay 15, 2024 | globenewswire.comRenalytix Reports Financial Results for Third Quarter of Fiscal Year 2024May 15, 2024 | markets.businessinsider.comRenalytix AI is about to announce its earnings — here's what Wall Street expectsJuly 27, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.May 14, 2024 | markets.businessinsider.comRenalytix AI earnings: here's what Wall Street expectsMay 9, 2024 | finance.yahoo.comRenalytix to Report Financial Results for Third Quarter Fiscal Year 2024 on May 15May 9, 2024 | globenewswire.comRenalytix to Report Financial Results for Third Quarter Fiscal Year 2024 on May 15April 28, 2024 | finance.yahoo.comRenalytix Plc (RNLX) Stock Price, News, Quote & History - Yahoo FinanceApril 17, 2024 | msn.comRenalytix files to sell 19.99M ordinary shares for holdersApril 9, 2024 | marketwatch.comRenalytix Sells Stock to Raise Up to $4 MlnApril 8, 2024 | globenewswire.comRenalytix Announces Financing with Expected Size of up to $4 MillionMarch 25, 2024 | investorplace.com3 Ridiculously Enticing Stocks to Buy for Under a BuckMarch 14, 2024 | stockhouse.comKidneyIntelX(TM) included in Final KDIGO 2024 Clinical Guideline for Chronic Kidney Disease (CKD)See More Headlines Receive RNLX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Renalytix and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/15/2024Today7/26/2024Next Earnings (Estimated)9/26/2024Fiscal Year End6/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorComputer and Technology Industry Medical laboratories Sub-IndustryHealthcare Current SymbolNASDAQ:RNLX CUSIPN/A CIK1811115 Webwww.renalytixai.com Phone44-20-3139-2910FaxN/AEmployees100Year FoundedN/APrice Target and Rating Average Stock Price Target$3.00 High Stock Price Target$3.00 Low Stock Price Target$3.00 Potential Upside/Downside+753.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.39) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-45,610,000.00 Net Margins-1,687.80% Pretax Margin-1,687.44% Return on Equity-1,008.88% Return on Assets-205.46% Debt Debt-to-Equity RatioN/A Current Ratio0.42 Quick Ratio0.42 Sales & Book Value Annual Sales$3.40 million Price / Sales7.98 Cash FlowN/A Price / Cash FlowN/A Book Value$0.15 per share Price / Book2.34Miscellaneous Outstanding Shares77,180,000Free Float63,059,000Market Cap$27.13 million OptionableOptionable Beta2.78 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. James R. McCullough M.B.A. (Age 56)Chief Executive Officer Comp: $1.04MMr. Oliver James Sterling IIIChief Financial OfficerMr. Fergus Fleming (Age 56)Chief Technology Officer Mr. Salim Gulamabbas Hamir F.C.A.Company SecretaryKey CompetitorsBurning Rock BiotechNASDAQ:BNREnzo BiochemNYSE:ENZExagenNASDAQ:XGNPsychemedicsNASDAQ:PMDBioNexus Gene LabNASDAQ:BGLCView All Competitors RNLX Stock Analysis - Frequently Asked Questions How have RNLX shares performed this year? Renalytix's stock was trading at $0.39 at the start of the year. Since then, RNLX stock has decreased by 9.9% and is now trading at $0.3515. View the best growth stocks for 2024 here. How were Renalytix's earnings last quarter? Renalytix Plc (NASDAQ:RNLX) announced its earnings results on Wednesday, May, 15th. The company reported ($0.08) earnings per share (EPS) for the quarter. The business had revenue of $0.54 million for the quarter. Renalytix had a negative trailing twelve-month return on equity of 1,008.88% and a negative net margin of 1,687.80%. When did Renalytix IPO? Renalytix (RNLX) raised $156 million in an initial public offering on Friday, July 17th 2020. The company issued 11,000,000 shares at $14.22 per share. J.P. Morgan and Stifel acted as the underwriters for the IPO. How do I buy shares of Renalytix? Shares of RNLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Renalytix own? Based on aggregate information from My MarketBeat watchlists, some other companies that Renalytix investors own include Trevena (TRVN), Advanced Micro Devices (AMD), ChromaDex (CDXC), Chimerix (CMRX), CTI BioPharma (CTIC). This page (NASDAQ:RNLX) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredThe #1 Crypto for 2024 (3 Cent Coin)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Renalytix Plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Renalytix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
